Drug Profile
Research programme: small molecule therapeutics - Syntrix Biosystems
Alternative Names: Multidrug-resistant tuberculosis therapy; SX-576Latest Information Update: 07 Feb 2019
Price :
$50
*
At a glance
- Originator Syntrix Biosystems
- Developer Syntrix Biosystems; University of Toronto
- Class Amides; Antiasthmatics; Antibacterials; Antituberculars; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Dihydrofolate synthetase inhibitors; Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Lung disorders; Tuberculosis
Most Recent Events
- 07 Feb 2019 No development reported - Preclinical for Asthma in USA (PO) Syntrix Biosystems pipeline, February 2019
- 16 May 2017 Syntrix Biosystems plans a phase I trial for SX 682 in combination with pembrolizumab in Melanoma (Late-stage disease, Metastatic disease, Combination therapy) in USA (NCT03161431)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-disorders in USA